Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIROTOX: Spironolactone for Prevention of Anthracycline-induced Cardiotoxicity
NCT06005259Phase 4Not yet recruiting
- Sponsor
- Universidade de São Paulo
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of spironolactone in anthracycline-induced cardiotoxicity, sponsored by Universidade de São Paulo. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
spironolactone
03
Conditions
anthracycline-induced cardiotoxicity
Beyond the preview
Go deeper on NCT06005259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06005259.